A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 308 participants.
Also called NCT07803679
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 308 participants
- Sponsor
- Registry
-
NCT07803679
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07803679. Randomized; single masking; primary purpose treatment. Start 2027-01-31 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
- Condition
- Coronary Artery Disease
- Condition
- Hypercholesterolemia
- Condition
- Atheroma
- Condition
- Atherosclerotic Plaque
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Routine Lipid Management
- Intervention (Device)
- Autoinjector
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct07803679- Content hash
b1d86758a83065fcd81ba9c6ceede28d9aa80d488c2769227bfee78b543ba9ad